Commonwealth Neuroendocrine Tumour Research Collaboration and the North American Neuroendocrine Tumor Society Guidelines for the Diagnosis and Management of Patients With Lung Neuroendocrine Tumors: An International Collaborative Endorsement and Update of the 2015 European Neuroendocrine Tumor Society Expert Consensus Guidelines.

Bronchial neuroendocrine tumors/tumours Consensus statements Guidelines Lung carcinoids Lung neuroendocrine tumors/tumours

Journal

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
ISSN: 1556-1380
Titre abrégé: J Thorac Oncol
Pays: United States
ID NLM: 101274235

Informations de publication

Date de publication:
10 2020
Historique:
received: 06 12 2019
revised: 14 06 2020
accepted: 29 06 2020
pubmed: 15 7 2020
medline: 2 2 2021
entrez: 15 7 2020
Statut: ppublish

Résumé

Lung neuroendocrine tumors (LNETs) are uncommon cancers, and there is a paucity of randomized evidence to guide practice. As a result, current guidelines from different neuroendocrine tumor societies vary considerably. There is a need to update and harmonize global consensus guidelines. This article reports the best practice guidelines produced by a collaboration between the Commonwealth Neuroendocrine Tumour Research Collaboration and the North American Neuroendocrine Tumor Society. We performed a formal endorsement and updating process of the 2015 European Neuroendocrine Tumor Society expert consensus article on LNET. A systematic review from January 2013 to October 2017 was conducted to procure the most recent evidence. The stepwise endorsement process involved experts from all major subspecialties, patients, and advocates. Guided by discussion of the most recent evidence, each statement from the European Neuroendocrine Tumor Society was either endorsed, modified, or removed. New consensus statements were added if appropriate. The search yielded 1109 new publications, of which 230 met the inclusion criteria. A total of 12 statements were endorsed, 22 statements were modified or updated, one was removed, and two were added. Critical answered questions for each topic in LNET were identified. Through the consensus process, guidelines for the management of patients with local and metastatic neuroendocrine tumors have been updated to include both recent evidence and practice changes relating to technological and definitional advances. The guidelines provide clear, evidence-based statements aimed at harmonizing the global approach to patients with LNETs, on the basis of the principles of person-centered and LNET-specific care. The importance of LNET-directed research and person-centered care throughout the diagnosis, treatment, and follow-up journey is emphasized along with directions for future collaborative research.

Identifiants

pubmed: 32663527
pii: S1556-0864(20)30548-7
doi: 10.1016/j.jtho.2020.06.021
pii:
doi:

Types de publication

Journal Article Review Systematic Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

1577-1598

Informations de copyright

Copyright © 2020. Published by Elsevier Inc.

Auteurs

Simron Singh (S)

Odette Cancer Centre, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada. Electronic address: Simron.singh@sunnybrook.ca.

Emily K Bergsland (EK)

Department of Medicine, Division of Hematology/Oncology, University of California, San Francisco, San Francisco, California.

Cynthia M Card (CM)

Tom Baker Cancer Centre, Calgary, Alberta, Canada.

Thomas A Hope (TA)

Department of Radiology and Biomedical Imaging, Division of Hematology/Oncology, University of California, San Francisco, San Francisco, California.

Pamela L Kunz (PL)

Department of Medicine, Yale University, New Haven, Connecticut.

David T Laidley (DT)

Department of Medical Imaging, Division of Nuclear Medicine, London Health Sciences Centre, London, Ontario, Canada.

Ben Lawrence (B)

Discipline of Oncology, University of Auckland, Auckland, New Zealand.

Simone Leyden (S)

Unicorn Foundation, Blairgowrie, Victoria, Australia.

David C Metz (DC)

Department of Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania.

Michael Michael (M)

Peter MacCallum Cancer Centre, University of Melbourne, Melbourne, Victoria, Australia.

Lucy E Modahl (LE)

Auckland Radiology Group, Auckland City Hospital, Auckland, New Zealand.

Sten Myrehaug (S)

Odette Cancer Centre, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada.

Sukhmani K Padda (SK)

Stanford Cancer Institute, Stanford University School of Medicine, Stanford, California.

Rodney F Pommier (RF)

Oregon Health & Science University, Portland, Oregon.

Robert A Ramirez (RA)

Department of Medical Oncology, Ochsner Medical Center, New Orleans, Louisiana.

Michael Soulen (M)

Abramson Cancer Center, University of Pennsylvania, Philadelphia, Pennsylvania.

Jonathan Strosberg (J)

Moffitt Cancer Center, Tampa, Florida.

Arthur Sung (A)

Department of Medicine, Division of Pulmonary, Allergy and Critical Care Medicine, Stanford University, Stanford, California.

Alia Thawer (A)

Odette Cancer Centre, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada.

Benjamin Wei (B)

Department of Surgery, Birmingham Medical Center, University of Alabama, Birmingham, Alabama.

Bin Xu (B)

Odette Cancer Centre, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada.

Eva Segelov (E)

Department of Oncology, Monash Health, Monash University, Melbourne, Victoria, Australia.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH